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Dravet syndrome is a severe epilepsy syndrome characterized by infantile onset of therapy-resistant, fever-sensitive seizures followed by
cognitive decline. Mutations in SCN1A explain about 75% of cases with Dravet syndrome; 90% of these mutations arise de novo. We
studied a cohort of nine Dravet-syndrome-affected individuals without an SCN1A mutation (these included some atypical cases with
onset at up to 2 years of age) by using whole-exome sequencing in proband-parent trios. In two individuals, we identified a de novo
loss-of-function mutation in CHD2 (encoding chromodomain helicase DNA binding protein 2). A third CHD2mutation was identified
in an epileptic proband of a second (stage 2) cohort. All three individuals with a CHD2 mutation had intellectual disability and fever-
sensitive generalized seizures, as well as prominent myoclonic seizures starting in the second year of life or later. To explore the
functional relevance of CHD2 haploinsufficiency in an in vivo model system, we knocked down chd2 in zebrafish by using targeted
morpholino antisense oligomers. chd2-knockdown larvae exhibited altered locomotor activity, and the epileptic nature of this
seizure-like behavior was confirmed by field-potential recordings that revealed epileptiform discharges similar to seizures in affected
persons. Both altered locomotor activity and epileptiform discharges were absent in appropriate control larvae. Our study provides
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Epileptic encephalopathies (EEs) are severe, intractable
childhood epilepsies with concomitant cognitive impair-
ment and other associated comorbidities. Although a
broad range of exogenous factors can lead to EE, in a signif-
icant subset of affected individuals the etiology remains
unidentified and might be endogenous. Consequently, a
genetic cause is assumed.1 Among the various EEs of
genetic origin, Dravet syndrome (MIM 607208) has
emerged as one of the best-defined phenotypes and the
one with the highest mutation detection yield. Children
with Dravet syndrome are prone to repetitive and pro-
longed epileptic seizures in the setting of fever.2 Although
these fever-induced seizures start around the age of
6 months (range ¼ 3–16 months),3 other seizure types
occur during the course of the disease, and developmental
plateauing is typical in the second year of life.
Taking into account SCN1A abnormalities due to single
or multiple exons deletions, de novo mutations in
SCN1A (MIM 182389) are known to cause Dravet syn-
drome in ~75% of affected probands.4 Despite this high
probability of identifying a mutation in an individual
with a typical phenotype, up to 25% of affected persons
do not carry SCN1A mutations, suggesting the involve-
ment of other genes. Mutations in PCDH19 (MIM
300460) can result in a Dravet-syndrome-like phenotype
in females and explain some of the cases without an
SCN1Amutation.5 For a relevant subset of probands, how-
ever, a causative mutation cannot be identified in either
gene. We therefore explored the involvement of mutations
in additional genes in these probands by using whole-
exome sequencing in proband-parent trios. This approach
provides the possibility of querying the entire exome for
de novo mutations in simplex cases, which has been
proven to be successful for intellectual disability, schizo-
phrenia, autism, and some forms of epilepsy or epilepsy-
related disorders.6,7
We first studied nine Dravet-syndrome-affected individ-
uals in whom SCN1A sequence mutations or copy-number
variations had been excluded. These probands were
selected on the basis of broad inclusion criteria, extending
the onset age of seizures to an age between 3 months and
2 years of life. Further inclusion criteria consisted of (1)
the presence of both febrile and afebrile seizures; (2)
multiple seizure types including tonic-clonic, hemiclonic,
myoclonic, absence, and/or focal seizures; (3) pharmacore-
sistant epilepsy at least during childhood or frequent status
epilepticus; (4) normal development prior to epilepsy
onset, although some minor degree of developmental
delay could be present; and (5) slowing or stagnation of
development after onset of seizures and absence of epilep-
togenic lesions on brain MRI.
Signed informed consent was obtained from all study
participants or their legal representatives. The local ethical
committees of theUniversity of Antwerp andAntwerpUni-
versity Hospital, University of Kiel, and other collaborating
centers approved this study. Genomic DNA was extracted
from peripheral blood according to standard procedures.968 The American Journal of Human Genetics 93, 967–975, NovembWe performed whole-exome sequencing on genomic
DNA of the nine selected individuals with Dravet syn-
drome and both unaffected parents at the Wellcome Trust
Sanger Institute (Hinxton, Cambridgeshire). In brief,
genomic DNA (~3 mg) was fragmented by sonication, and
fragments with a length of 150–200 bp were purified. After
a paired-end DNA library was prepared from the DNA frag-
ments (with the TruSeq DNA Sample Preparation Kit from
Illumina), targeted enrichment was performed with the
SureSelect Human All Exon 50Mb Kit (Agilent Technolo-
gies). Captured DNA was then sequenced on a HiSeq2000
(Illumina) as paired-end 75 bp reads according to the
manufacturer’s protocol. Sequencing reads passing quality
filtering were aligned to the human reference genome
(hg19, UCSC Genome Browser) with the Burrows-Wheeler
Aligner.8 The Genome Analysis Toolkit (GATK)9 was used
to recalibrate base quality scores, realign around indels,
and mark duplicate reads. Independent variant calling
was performed on the mapped reads with SAMtools10
mpileup, GATK UnifiedGenotyper, and Dindel.11 The
GenomeComb12 program was used for annotating, com-
paring, and filtering the data. For de novo variant calling,
the DeNovoGear13 program by Conrad and colleagues
was used and double-checked by GenomeComb analysis.
Our analysis revealed a heterozygous de novo mutation
in CHD2 (MIM 302119; RefSeq accession number
NM_001271.3), encoding chromodomain helicase DNA
binding protein 2 (CHD2; RefSeq NP_001262.3), in two
out of nine probands. One individual carried a nonsense
mutation, c.4971G>A (p.Trp1657*), in exon 38; the sec-
ond person carried a splice-site mutation, c.18102A>C,
affecting the splice acceptor site of exon 16. Presence or
absence of the mutations was confirmed on genomic
DNA of the probands or parents, respectively, by bidirec-
tional Sanger sequencing using the ABI BigDye Terminator
v.3.1 cycle sequencing kit on an ABI 3730xl automated
DNA Analyzer (Applied Biosystems).
To obtain further genetic evidence of pathogenicity, we
performed a mutation analysis of all 39 coding exons
and intron-exon boundaries of CHD2 by using bidirec-
tional sequencing (primer sequences are available upon
request) in a cohort of 150 EE probands similar to the
two individuals carrying a CHD2 mutation: all selected
probands had infantile- or childhood-onset epilepsy with
subsequent developmental delay. All individuals had
normal brain MRI and at least one of the following seizure
types: tonic-clonic seizures, myoclonic seizures, (atypical)
absence seizures, or atonic seizures. In this cohort, we iden-
tified a third person carrying a de novo mutation in CHD2
(c.1396C>T [p.Arg466*]) in exon 13.
The two identified premature stop codons are predicted
to result in degradation of the mutant transcript by means
of nonsense-mediated mRNA decay (NMD). The effect of
the splice-site mutation on transcript level is unclear, given
that both exon skipping and (partial) intron retention are
possible. Most likely, the splice acceptor mutation results
in skipping of exon 16 and a subsequent out-of-frameer 7, 2013
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.deletion of exon 16, leading to a premature stop codon in
exon 17 (p.Thr604Valfs2*). Therefore, NMD could also be
active in this case. To test the NMD hypothesis, we ex-
tracted RNA from fresh blood (QIAGEN RNeasy Micro
Kit) of the three probands and a parent as a control individ-
ual, removed contaminated DNA by Ambion DNA-free
DNase treatment (Life Technologies), and synthesized
cDNA by Superscript III reverse transcriptase (Life Technol-
ogies). For the two nonsense mutations, we performed
bidirectional sequencing on cDNA with primers flanking
the mutation. With these experiments, we were able to
detect the mutation with a 50/50 ratio, proving that the
aberrant allele was not degraded by NMD. These results
were confirmed by Sybr-Green-based quantitative PCR
(qPCR) experiments (Sigma-Aldrich) with six primer pairs
complementary to CHD2 cDNA (data not shown). For
the splice-site mutation, we performed qPCR and devel-
oped sequencing primers flanking exon 16 on cDNA.
Also here, qPCR showed the presence of both alleles.
Additionally, the sequencing experiment showed an
abundance of alternative splicing events in the probands
compared to the control individual, but the consequence
of the alternative splicing remained unknown. Although
skipping of exon 16 appeared to be a logical consequence,
additional investigations revealed more complex alterna-
tive splicing events. Whereas definite identification of all
alternatively spliced transcripts was not possible, we were
able to rule out NMD. We assumed that either the aberrant
proteins were degraded by the proteasome or the shorter
proteins were not fully functional; both of these cases
would result in loss of function. In support of the pathoge-
nicity of these mutations, none of the identifiedmutations
have been observed in the 1000 Genomes Project, Na-
tional Heart, Lung, and Blood Institute Exome Sequencing
Project Exome Variant Server (EVS), or dbSNP (build 137).
Furthermore, splice-site, frameshift, or nonsense variations
are absent in the EVS and 1000 Genomes Project cohorts.
Between the age of 14 months and 3.5 years, the three
persons carrying a de novo CHD2 mutation presented
with febrile seizures followed by therapy-resistant general-
ized seizures (Table 1). Frequent myoclonic seizures, gener-
alized tonic-clonic seizures (GTCSs), and absences were
seen in all three individuals. Proband 1 developed nor-
mally during the first year of life. The first febrile seizure
occurred when he was 14 months old and was soon fol-
lowed by afebrile head drops occurring several times a
day. When he was 2 years old, therapy-resistant myoclonic
seizures, atypical absences, and GTCSs rarely associated
with fever developed. On one occasion, he had a status
epilepticus. Electroencephalography (EEG) showed gener-
alized polyspike wave discharges and, later, focal epileptic
discharges. He has been treated with valproic acid, levetir-
acetam, phenytoin, topiramate, bromide, phenobarbital,
ethosuximide, topiramate, vitamine B6, and prednisolon.
He now has moderate intellectual disability (ID), dysar-
thria, and ataxia. Proband 2 had a normal early develop-
ment. At the age of 2 years, she had a cluster of febrileThe American Journal of Human Genetics 93, 967–975, November 7, 2013 969
seizures. At the age of 2.5 years, she developed therapy-
resistant absence seizures accompanied by eyelid myoclo-
nias, myoclonic seizures, and febrile and afebrile GTCSs.
EEG showed frequent generalized spike-wave complexes
and polyspikes. She has been treated with vigabatrin, val-
proate, bromide, ethosuximide, lamotrigine, and levetira-
cetam and is currently taking a combination of topiramate
and valproic acid. She still has afebrile GTCSs and moder-
ate ID. Proband 3 had slightly delayed early motor and
speech development, given that he walked at the age of
1.5 years and produced his first words at the age of 2 years.
At the age of 3.5 years, he had two GTCSs during an
episode of high fever. During the following 2 years,
he had pharmacoresistant febrile and afebrile GTCSs,
hemiclonic, atonic, and myoclonic seizures, and atypical
absences. He was treated with valproic acid, topiramate,
and levetiracetam. After the start of clobazam at the age
of 5.5 years, he became seizure free. EEG showed general-
ized (poly)spike-wave complexes. After seizure onset, a
cognitive decline was seen but partially improved when
seizures were controlled. He now has mild ID, autism spec-
trum disorder (ASD), attention deficit hyperactivity disor-
der, and mild ataxia. Brain MRI was normal in probands
1 and 2 and showed atrophic changes in proband 3.
In addition to our three individuals with a CHD2 muta-
tion, one simplex case with ID and absence epilepsy and
one simplex ASD case both carrying a mutation in CHD2
have been reported in the literature.14,15 Recently, two
other research groups have also shown the involvement
of CHD2 mutations in EEs.16,17 Furthermore, several indi-
viduals affected by IDandgeneralized epilepsy and carrying
a multigenic chromosomal deletion of 15q26.2, including
CHD2, have been described (Table 2).18–22 The presumed
haploinsufficiency of CHD2 in these probands prompted
us to screen all individuals without a previous detected
mutation from both studied cohorts for copy-number vari-
ants in CHD2 with the multiplex amplicon quantification
(MAQ) technique, an in-house-developed technique based
on a semiquantified multiplex PCR. The multiplex PCR
reaction consisted of six target amplicons located in the
genomic region of CHD2 and four reference amplicons
randomly located on different chromosomes. The MAQ
analysis was performed as described previously.23 A partial
or full deletion or duplication of the genewas not identified
in any of the remaining studied persons (7 of the initial
cohort and 149 of the second-stage cohort).
To establish additional evidence of the implication of
CHD2 in the development of epilepsy, we examined the
functional consequence of CHD2 haploinsufficiency by
knocking down chd2 in zebrafish by using targeted mor-
pholino (MO) antisense oligomers.24 All zebrafish experi-
ments carried out were approved by the ethics committee
of the University of Leuven (Ethische Commissie van de
KU Leuven, approval number P05090) and by the Belgian
Federal Public Service of Health, Food Chain Safety, and
Environment (Federale Overheidsdienst Volksgezondheid,
Veiligheid van de Voedselketen en Leefmileu, approval970 The American Journal of Human Genetics 93, 967–975, Novembnumber LA1210199). In order to mimic loss-of-function
mutations, we designed a MO (E2I2 MO, 50-GATCAGA
CTGGCCTTTTTGTGTACC-30) to target the splice donor
site of exon 2 and interfere with normal pre-mRNA
splicing of zebrafish chd2 (ENSDART00000127730). Target-
ing of the exon 2-intron 2 boundary should result in
abnormal exon 2 splicing, leading to its complete or partial
deletion together with its flanking introns. This should
result in an mRNA shorter than the wild-type transcript
(Figure 1). A control MO (randomized 25 N oligomer)
was used as a negative control (ctrl MO). All MOs were de-
signed and synthesized by GeneTools. Gene knockdowns
were achieved through microinjection of MOs into 1- to
2-cell-stage embryos from the AB (wild-type) strain accord-
ing to the method previously described.25 In order to
mimic haploinsufficiency, we titrated the amount of E2I2
MO to 9 ng per injection so as to reduce correctly spliced
chd2 mRNA levels by approximately 50%. The same
amount of ctrl MO was injected into sibling control
embryos. To evaluate the level of knockdown in zebrafish
embryos and larvae, we performed qPCR on splice-blocked
pre-mRNA. Total mRNA was purified from each of 10 ctrl-
MO- and E2I2-MO-injected embryos and larvae between
1 and 5 days postfertilization (dpf) with TRIzol reagent
(Life Technologies) according to the recommended proto-
col. Reverse transcription of 2 mg total RNA to single-
stranded cDNA was performed with the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems).
The PCR reaction was performed with Phusion Polymerase
(ThermoScientific) and chd2-specific primers (50-AAGAC
GAAGGCTCGACTCAA-30 and 50-TGCAGGCTCTTGTCTA
CTGC-30) for detecting the amplicon with or without the
partially deleted exon 2. PCR products were visualized
with standard agarose gel electrophoresis. As expected,
the ctrl MO did not have any effect on splicing and re-
sulted in the predicted wild-type mRNA corresponding to
a 384 bp PCR product (Figure 1). chd2 knockdown using
the E2I2 MO resulted in two products: (1) a 384 bp
band corresponding to the wild-type mRNA and (2) a
shorter product (~300 bp) probably corresponding to an
abnormally spliced mRNA, suggesting a partial knock-
down. The discrepancy between the length of predicted
(149 bp) versus observed (~300 bp) abnormally spliced
mRNAwas most likely a result of the activation of a cryptic
splice site in exon 2 instead of splicing to the 50 end of the
upstream splice site (this could cause a partial deletion of
exon 2). This abnormal product appeared after 1 dpf and
was sustained until 5 dpf. Adult zebrafish (Danio rerio) of
the AB strain (Zebrafish International Resource Center,
Eugene) were maintained at 28.5C on a 14/10 hr light/
dark cycle under standard aquaculture conditions, and
fertilized eggs were collected via natural spawning.
Embryos were raised in embryo medium consisting of
1.5 mM HEPES, pH 7.6, 17.4 mM NaCl, 0.21 mM KCl,
0.12 mMMgSO4, and 0.18 mM Ca(NO3)2) in an incubator
on a 14/10 hr light/dark cycle at 28.5C. For all experi-
ments described, larvae of 1–5 dpf were used.er 7, 2013
Table 2. Clinical Phenotype of Probands Reported in Literature with CHD2 Deletions or Mutations
Reference
Capelli et al.18 Dhamija et al.19 Veredice et al.20 Li et al.21 Lund et al.22 Rauch et al.14 Carvill et al.16 Allen et al.17
Number of
individuals
1 1 1 1 1 1 6 1
Genetic findings de novo 0.5 Mb
deletion including
CHD2 and RGMA
de novo 0.9 Mb
deletion including
CHD2 and three
other genes
de novo 5 Mb
deletion including
CHD2 and 55 other
genes
3.3 Mb deletion
including CHD2
and 17 other genes
(no segregation
analysis)
2 Mb deletion including
CHD2 and seven other
genes. Also carried five
additional deletions and
duplications, including
a total of 100 genes
(paternal DNA not
available)
de novo frameshift
mutation c.1809 del
(p.Thr604Leufs*19)
four de novo frameshift
and two de novo
missense alterations:
p.Glu1412Glyfs*64,
p.Arg121*, p.Gly491Valfs*13,
p.Arg1644Lysfs*22,
p.Trp548Arg, p.Leu823Pro
de novo splice
mutation
c.1502þ1G>A
Age at seizure
onset
2 years 3.5 years 6 months not specified 4 years 5 years 1–3 years 6 months
Seizure type at
onset
not specified CPSs febrile generalized
clonic SE
two episodes of FSs atypical ASs, MSs ASs atypical ASs, AtSs, MSs,
GTCSs, FSs, FDSs
unknown
Further seizure
types
not specified therapy-resistant
ASs with eyelid
flutter, TSs, MSs,
GTCSs
therapy-resistant
massive MSs with
head drop, eyelid
MSs, prolonged
hemiclonic FSs
none TSs, MSs, atypical ASs,
nonconvulsive SE
not specified FSs, AtSs, MSs, GTCSs, NCS,
SE, TSs, HSs, FDSs, MAs,
atypical ASs
MSs, FDSs, GTCSs,
atypical ASs, AtSs
Fever sensitivity not specified no yes yes no not specified one patient no
EEG generalized spike
waves and focal
discharges
generalized spike
waves, PPR
irregular generalized
spike waves, PPR
not specified generalized slow spike
waves and runs of fast
spikes
not specified generalized (poly)spike waves,
slow spike waves, multifocal
discharges, generalized
paroxysmal fast activity,
diffuse slowing
slow background,
generalized spike
waves
MRI normal normal vermis hypoplasia,
cisterna magna
normal partial agenesis of vermis unknown unknown normal
Development
prior to epilepsy
not specified delayed delayed delayed delayed delayed normal or delayed normal
Developmental
outcome
globally delayed,
severe speech
impairment
mild ID mild ID mild to moderate
ID, speech
impairment
severe ID mild ID moderate to severe ID unspecified delay
Other clinical
findings
ataxia, relative
microcephaly, mild
facial dysmorphisms
microcephaly,
short stature,
mild facial
dysmorphisms
microcephaly,
congenital
hypothyroidism,
bicuspid aortic valve,
hypotonia
microcephaly,
short stature,
mild facial
dysmorphisms
short stature, hypertelorism,
epicantal fold, micropenis,
single palmar creases
Duane anomaly
Abbreviations are as follows: AS, absence seizure; AtS, atonic seizure; CPS, complex partial seizure; FDS, focal dyscognitive seizure; FS, febrile seizure; GTCS, generalized tonic-clonic seizure; HS, hemiclonic seizure; ID, in-
tellectual disability; MA, myoclonic absence; MS, myoclonic seizure; NCS, nonconvulsive status epilepticus; PPR, photo paroxysmal response; SE, status epilepticus; and TS, tonic seizure.
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Figure 1. chd2 Knockdown: E2I2 MO Causes Missplicing of Zebrafish chd2
(A) Schematic cartoon showing predicted splicing events in the pre-mRNA of chd2 E2I2-MO- and ctrl-MO-injected fish. The exons are
represented by colored boxes (E1, E2, and E3), and the introns are represented by solid black lines (I1 and I2). The splice MO binding site
(E2I2 MO) and the primer binding sites (P1 and P2) used for qPCR are indicated. According to the predictions, PCR products of 384 and
149 bp were expected for ctrl-MO- and E2I2-MO-injected larvae, respectively. In the case of a partial knockdown, both products should
be present.
(B) qPCR analysis of MO-knockdown larvae. Normal splicing in ctrl-MO-injected larvae resulted in the predicted 384 bp product, indi-
cating the presence of wild-type mRNA. Abnormal splicing in E2I2-MO-injected larvae resulted in two products: 384 bp (corresponding
to the wild-type mRNA) and ~300 bp (an abnormal mRNA), indicating partial knockdown. The larger-than-expected size of the PCR
product could have been a result of the activation of a cryptic splice site. The aberrant mRNA was present from 1–5 dpf and was accom-
panied by the wild-type 384 bp fragment.E2I2-MO-injected larvae exhibited prominent morpho-
logical and behavioral alterations. The E2I2-MO-injected
larvae showed from 2 dpf onward multiple developmental
abnormalities: pericardial edema, microcephaly, body
curvature, absent swim bladder, and stunted growth (Fig-972 The American Journal of Human Genetics 93, 967–975, Novembure 2). The ctrl-MO-injected larvae were morphologically
indistinguishable from the uninjected ones. Visual obser-
vation of chd2 knockdown larvae by means of high-magni-
fication stereomicroscopy revealed that all 4 dpf larvae
displayed abnormal movement patterns with frequentFigure 2. Representative Pictures of
4-Day-Old chd2 Knockdown and Control
Larvae
chd2 E2I2-MO-injected larvae displayed
pericardial edema, microcephaly, body
curvature, absent swim bladder, and
stunted growth (A). Ctrl-MO-injected (B)
and uninjected (C) larvae developed
normally. The experiment was performed
at least three times with 100 embryos
injected per condition.
er 7, 2013
Figure 3. Electrographic Activity of 4-Day-Old chd2 Knockdown
and Control Larvae
(A) Uninjected larva.
(B) chd2 E2I2-MO-injected larva displaying ictal-like discharges.
(C) Ctrl-MO-injected larva.
One-minute fragments are shown. The y axis shows a 4 mV
span. Ictal-like events shown in (B) (more than 3 s in duration)
were observed in five out of seven fish larvae in the chd2
E2I2-MO-injected group.26 Seven, six, and five fish were ana-
lyzed for the chd2 E2I2 MO, ctrl MO, and uninjected larvae,
respectively.whirlpool-like events. Occasionally, we also noticed pecto-
ral-fin and jaw twitching and whole-body trembling. To
confirm whether this behavior could have been a result
of seizure activity, we performed field-potential recordings
on larval tecta as described previously.26 Already from
4 dpf, E2I2-MO-injected larvae displayed epileptiform dis-
charges (Figure 3). Discharges consisted of multiple up-
ward spikes of amplitudes several times larger than those
of ctrl-MO-injected or uninjected larvae and with occa-
sional ictal-like patterns. This spiking pattern resembled
preictal discharges observed in immature hippocampi of
a mouse model of temporal lobe epilepsy.27 These experi-The Americanmental findings suggest that loss of CHD2 results in an
epilepsy phenotype.
CHD2 encodes CHD2, a protein that does not have an
established link to neuronal function or hyperexcitability.
CHD proteins are assumed to modify gene transcription
by affecting chromatin structure through helicase func-
tion. A Chd2-deficient mouse model has been reported to
show spinal abnormalities, renal dysfunction, growth
retardation, and susceptibility to tumors, but not epileptic
seizures.28,29 None of the features described in the mouse
model were seen in the probands with de novo CHD2
mutations, suggesting that in contrast to the zebrafish
model presented here, the existing mouse model insuffi-
ciently replicates the human phenotype. On the other
hand, in addition to showing electrographic seizures
observed in zebrafish chd2 knockdowns, these larvae dis-
played edemas, body curvature, and stunted growth that
could be considered equivalent to the cardiovascular and
renal defects, lord kyphosis, and postnatal stunted-growth
phenotypes described in Chd2 mouse mutants.28,30,31
Thus, the zebrafish phenocopies aspects of both the
human and the mouse spectra. Why no seizure phenotype
has been reported for Chd2 mutant mice remains to be
determined. Perhaps these mice have to be monitored
with EEG for seizure detection and/or challenged before
(presumably) spontaneous seizure behavior can be de-
tected. Additionally, mutations in other genes encoding
members of the CHD family have been identified, such
as CHD7 mutations in persons with CHARGE syn-
drome32 and de novo mutations in CHD3, CHD7, and
CHD8 in individuals with ASD.33,34 Although the exact
role of CHD2 in neuronal hyperexcitability remains to be
determined, our findings suggest that helicase dysfunction
might be a mechanism involved in epileptogenesis and
neurodevelopment.
In summary, we identified CHD2 nonsense mutations
as the underlying genetic defect for a fever-sensitive
myoclonic EE. In our study, individuals carrying a CHD2
mutation displayed a spectrum of fever-sensitive general-
ized seizures similar to those in Dravet syndrome, but
seizure onset was clearly later, and unlike in Dravet syn-
drome, developmental delay could be seen prior to epilepsy
onset. Future studies will reveal whether CHD2 mutations
also account for a subset of individuals with more typical
Dravet syndrome.We showed that aMO-based knockdown
of chd2 in zebrafish resulted in clinical and electrographic
seizures paralleling the human phenotype. Our study
further suggests that helicase dysfunction inhumansmight
specifically result in neuronal hyperexcitability in the
absence of syndromic or dysmorphic features.Consortia
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